Resumen

El objetivo de este estudio clínico es obtener más información sobre los efectos del cambio a los fármacos del estudio, la combinación de dosis fija (CDF) de bictegravir (BIC)/lenacapavir (LEN), en comparación con la terapia actual de CDF de bictegravir/emtricitabina/tenofovir alafenamida (B/F/TAF) en personas que viven con VIH-1 (PVV). El objetivo principal de este estudio es conocer la eficacia del cambio a comprimidos de CDF BIC/LEN en comparación con la continuación de comprimidos de CDF B/F/TAF en PVV con supresión virológica.

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

Currently receiving B/F/TAF for at least 6 months prior to screening.
If plasma human immunodeficiency virus type 1 (HIV-1) ribonucleic acid (RNA) measurements in the last 6 months prior to screening are available, all levels must be \< 50 copies/mL.
At least one documented HIV-1 RNA level measured between 6 and 12 months (± 2 months) prior to screening. This and any other HIV-1 RNA measurements documented in this period must be \< 50 copies/mL.
Plasma HIV-1 RNA levels \< 50 copies/mL at screening.
No documented or suspected resistance to BIC (including integrase strand-transfer inhibitor resistant (INSTI-R) mutations T66A/I/K, E92G/Q, G118R, F121Y, Y143C/H/R, S147G, Q148H/K/R, N155H/S, or R263K in the integrase gene).
No documented or suspected resistance to tenofovir alafenamide (TAF) (TAF; mutations K65R, K65N, K70E, Q151M or T69 insertion, or ≥ 3 of the following thymidine analog mutations \[M41L, D67N, K70R, L210W, T215Y/F, K219Q/E/N/R\] in the reverse transcriptase gene).
Estimated glomerular filtration rate ≥ 30 mL/min according to the Cockcroft-Gault formula for creatinine clearance.

Criterios de exclusión

Positive serum pregnancy test or pregnant at screening or a positive pregnancy test prior to Day 1 randomization.
Breastfeeding (nursing).
Prior use of, or exposure to, LEN.
Active, serious infections (other than HIV-1) requiring parenteral therapy \< 30 days prior to randomization.
Active tuberculosis infection.
Acute hepatitis \< 30 days before randomization.
Chronic hepatitis B virus (HBV) infection, as determined by either:
Positive HBV surface antigen and negative HBV surface antibody, regardless of HBV core antibody status, at the screening visit.
Positive HBV core antibody and negative HBV surface antibody, regardless of HBV surface antigen status, at the screening visit.
Known hypersensitivity to the study drug, its metabolites, or any formulation excipient.
History of or current clinical decompensated liver cirrhosis (eg, ascites, encephalopathy, or variceal bleeding).
Abnormal electrocardiogram (ECG) at the screening visit that is clinically significant as determined by the investigator.
Active malignancy requiring acute systemic therapy.
Any of the following laboratory values at screening:
Alanine aminotransferase \> 5 × upper limit of normal (ULN).
Direct bilirubin \> 1.5 × ULN.
Platelets \< 50,000/mm\^3.
Hemoglobin \< 8.0 g/dL.
Requirement for ongoing therapy with or prior use of any prohibited medications listed in the protocol.
Participation or planned participation in any other clinical study (including observational studies) without prior approval from the sponsor.
Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the participant unsuitable for the study or unable to comply with dosing requirements.

Intervenciones

drug